MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
Title:
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
Author:
Sadones, J. Michotte, A. Veld, P. Chaskis, C. Sciot, R. Menten, J. Joossens, E.J.R. Strauven, T. D’Hondt, L.A. Sartenaer, D. Califice, S.F.E.H. Bierau, K. Svensson, C. De Grève, J. Neyns, B.